Galeterone is a CYP17 Inhibitor for Prostate Cancer Research
Galeterone (TOK-001) is a multifunctional antiandrogen and CYP17 inhibitor for castration resistant prostate cancer (CRPC) research.
Galeterone (TOK-001) is a multifunctional antiandrogen and CYP17 inhibitor for castration resistant prostate cancer (CRPC) research.
CYP17A1 is a bifunctional hydroxylase that belongs to the cytochrome P450 family. It has 17α-hydroxylase and 17,20-lyase activities and is a key enzyme in the steroidogenic pathway that produces progestins,…
Prostate cancer (PCa) is one of the most prevalent malignancies in the world. Depending on the grade of cancer, a variable percentage of these patients experience progression to castration-resistant prostate…
IGF, an insulin-like growth factor, regulates cell growth, proliferation, and survival. The IGF system is made up of IGF1, IGF2, insulin, and corresponding receptors. It transmits abnormal signals to cause…
Androgen receptors (ARs) mediate cell differentiation and development of prostate cancer. The target is a common therapeutic target in prostate cancer. Proxalutamide (GT0918) design is based on the core structure…
Fatty acid synthase (FASN) is a multi-enzyme protein that catalyzes the synthesis of fatty acids. Its main function is to catalyze the synthesis of palmitate (C16:0) from acetyl CoA and…
Prostate cancer arises as an androgen driven disease. Therefore the mainstay of systemic therapy for patients with advanced disease is androgen deprivation therapy. Despite of significant responses, nearly all patients…